Heron Therapeutics CEO Craig Collard Converts 13,797 RSUs

What Happened

• Craig A. Collard, CEO of Heron Therapeutics (HRTX), reported the exercise/conversion of a derivative on 2026-07-19. The filing shows 13,797 shares were acquired via conversion (code M) and 13,797 shares were reported disposed at $0.00. No cash value was reported for the transaction.

Key Details

• Transaction date: 2026-07-19; Form 4 filed: 2026-07-20 (timely).
• Reported lines: 13,797 shares acquired (conversion/exercise, price N/A) and 13,797 shares disposed at $0.00 (derivative).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: Each restricted stock unit (RSU) represents a contingent right to receive one share.
  • F2: These RSUs vest in 16 equal quarterly installments beginning 01/19/2024.
• Transaction code M denotes exercise or conversion of a derivative (e.g., conversion of RSUs).

Context

• This appears to be a conversion/settlement of RSUs into common stock rather than an open-market purchase or sale. The disposed line at $0.00 reflects how the conversion was reported, not an arm’s-length sale for cash. Conversions/vestings are routine for equity compensation and do not necessarily signal a change in insider sentiment.